NRA-TELMISARTAN TABLET

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

TELMISARTAN

Διαθέσιμο από:

NORA PHARMA INC

Φαρμακολογική κατηγορία (ATC):

C09CA07

INN (Διεθνής Όνομα):

TELMISARTAN

Δοσολογία:

40MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

TELMISARTAN 40MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

15G/50G

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0138223001; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2020-08-25

Αρχείο Π.Χ.Π.

_NRA-Telmisartan - Product Monograph _
_1 of 31 _
PRODUCT MONOGRAPH
PR
NRA-TELMISARTAN
Telmisartan Tablets
40 mg and 80 mg
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker
Nora Pharma Inc.
1565 Lionel-Boulet Blvd.
Varennes, Québec
J3X 1P7 Canada
SUBMISSION CONTROL NO.:
266032
Date of
Revision:
August 9, 2022
_NRA-Telmisartan - Product Monograph _
_2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................
14
DOSAGE AND ADMINISTRATION
.....................................................................................
16
OVERDOSAGE
.......................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 20
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.................................................................................
21
CLINICAL TRIALS
..............